Rhythm Pharmaceuticals, Inc.

Thank you.

Ladies and gentlemen, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals second quarter 2022 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone keypad. At this time, I would like to turn the conference over to Mr. Dave Connolly. Sir, please begin.

Thank you. I'm Dave Connolly, head of IR and corporate communications here at Rhythm Pharmaceuticals. For those of you participating via the conference call, the accompanying slides can be accessed and controlled by going to the events section of our investors page on our website at ir.rhythmtx.com. I'll remind you that this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially. from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly report on file with the SEC. In addition, any forward-looking statements represent our views as of today only and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. This morning, we issued a press release that provides our second quarter financial results and business update, which is now available on our website. On our call today and here with me in Boston are David Meeker, Chair, President, and Chief Executive Officer of Rhythm, Jennifer Chen, Executive Vice President, Head of North America, and our Chief Financial Officer, Hunter Schmidt. And calling in from France is Yann Mazzebro, Executive Vice President, Head of International today. With that, I'll turn the call over to David, who will begin on slide five.